Switch theme
Sign up to access all valuation multiples
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
1997
101
LTM Revenue $52.1M
LTM EBITDA $4.8M
$104M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PhotoCure has a last 12-month revenue (LTM) of $52.1M and a last 12-month EBITDA of $4.8M.
In the most recent fiscal year, PhotoCure achieved revenue of $51.4M and an EBITDA of $6.4M.
PhotoCure expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PhotoCure valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $52.1M | XXX | $51.4M | XXX | XXX | XXX |
| Gross Profit | $49.0M | XXX | $48.4M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $4.8M | XXX | $6.4M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $1.9M | XXX | $2.0M | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $0.3M | XXX | -$0.3M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PhotoCure's stock price is NOK 50 (or $5).
PhotoCure has current market cap of NOK 1.3B (or $131M), and EV of NOK 1.1B (or $104M).
See PhotoCure trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $131M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PhotoCure has market cap of $131M and EV of $104M.
PhotoCure's trades at 2.0x EV/Revenue multiple, and 16.3x EV/EBITDA.
Equity research analysts estimate PhotoCure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PhotoCure has a P/E ratio of 403.9x.
See valuation multiples for PhotoCure and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $131M | XXX | $131M | XXX | XXX | XXX |
| EV (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 21.8x | XXX | 16.3x | XXX | XXX | XXX |
| EV/EBIT | 55.1x | XXX | 52.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 403.9x | XXX | -399.9x | XXX | XXX | XXX |
| EV/FCF | 21.8x | XXX | 16.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPhotoCure's last 12 month revenue growth is 9%
PhotoCure's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.
PhotoCure's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PhotoCure's rule of X is 32% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PhotoCure and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 48% | XXX | -3% | XXX | XXX | XXX |
| Rule of 40 | 22% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 90% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PhotoCure acquired XXX companies to date.
Last acquisition by PhotoCure was XXXXXXXX, XXXXX XXXXX XXXXXX . PhotoCure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PhotoCure founded? | PhotoCure was founded in 1997. |
| Where is PhotoCure headquartered? | PhotoCure is headquartered in Norway. |
| How many employees does PhotoCure have? | As of today, PhotoCure has 101 employees. |
| Who is the CEO of PhotoCure? | PhotoCure's CEO is Mr. Daniel Schneider. |
| Is PhotoCure publicy listed? | Yes, PhotoCure is a public company listed on OSL. |
| What is the stock symbol of PhotoCure? | PhotoCure trades under PHO ticker. |
| When did PhotoCure go public? | PhotoCure went public in 2000. |
| Who are competitors of PhotoCure? | Similar companies to PhotoCure include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PhotoCure? | PhotoCure's current market cap is $131M |
| What is the current revenue of PhotoCure? | PhotoCure's last 12 months revenue is $52.1M. |
| What is the current revenue growth of PhotoCure? | PhotoCure revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of PhotoCure? | Current revenue multiple of PhotoCure is 2.0x. |
| Is PhotoCure profitable? | Yes, PhotoCure is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PhotoCure? | PhotoCure's last 12 months EBITDA is $4.8M. |
| What is PhotoCure's EBITDA margin? | PhotoCure's last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of PhotoCure? | Current EBITDA multiple of PhotoCure is 21.8x. |
| What is the current FCF of PhotoCure? | PhotoCure's last 12 months FCF is $4.8M. |
| What is PhotoCure's FCF margin? | PhotoCure's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of PhotoCure? | Current FCF multiple of PhotoCure is 21.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
